Open Access

Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties

  • Giuseppe Stirparo,
  • Fabio Palazzo,
  • Sergio De Filippis and
  • Paolo Martelletti
The Journal of Headache and PainOfficial Journal of the Italian Society for the Study of Headaches4:00019

https://doi.org/10.1007/s101940300019

Abstract

Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.

Key words TriptansIndications

Notes